AU Patent

AU2016332352A1 — Small molecules blocking histone reader domains

Assigned to Københavns Universitet · Expires 2018-04-12 · 8y expired

What this patent protects

The present invention relates to small molecules interfering with the conformational space of the TONSL ARD occupied by the histone H4 tail. These small molecules targets the binding pocket of TONSL encompassing the H4 residues K12- R23 and act by preventing or disrupting the bin…

USPTO Abstract

The present invention relates to small molecules interfering with the conformational space of the TONSL ARD occupied by the histone H4 tail. These small molecules targets the binding pocket of TONSL encompassing the H4 residues K12- R23 and act by preventing or disrupting the binding of the H4 tail K12- R23 with the TONSL ARD via direct competition or via allosteric disruption of the binding pocket. The present inventors have identified and solved the structure of a histone reader domain of TONSL termed the ARD (ankyrin repeat domain).

Drugs covered by this patent

Patent Metadata

Patent number
AU2016332352A1
Jurisdiction
AU
Classification
—
Expires
2018-04-12
Drug substance claim
No
Drug product claim
No
Assignee
Københavns Universitet
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.